Anshei Hair's Menrav Deal: Lower Funding Pressure and Less La Guardia Upside
The Menrav deal reduces Anshei Hair's funding pressure and concentration in La Guardia, the largest project in its backlog, but it is not a clean full-value crystallization. The company is exchanging 49% direct exposure for staged cash, a partner, and conditional replacement exposure in Ibn Gabirol projects.
The Menrav transaction changes how La Guardia should be read at Anshei Hair. It does not turn the largest project in the backlog into full cash value. It replaces full exposure and full funding responsibility with a partnership model: NIS 32 million in cash consideration, reimbursement of about NIS 3.5 million for investment already made, and shared funding and profit economics. That is real progress, because La Guardia is large relative to Anshei Hair's cash balance and quarterly cash flow, with expected revenue of about NIS 1.06 billion and expected gross profit of about NIS 210.3 million. But it is not a full value crystallization: the company is selling 49% of the project's rights and obligations, so part of the direct upside leaves before the project receives a building permit. The consideration also does not arrive all at once, and the replacement exposure in Ibn Gabirol still depends on tenant approvals and, in one case, a special majority signing by December 31, 2026. The current judgment is therefore narrow: the deal lowers La Guardia funding pressure and concentration, but it also makes Anshei Hair's future value less straightforward to measure. The next proof point is not the signing itself, but closing the conditions, receiving the scheduled payments, and moving La Guardia toward a permit.
La Guardia Is No Longer a Full-Exposure Project
La Guardia 35-45 is not just another backlog project. The project table shows 420 apartments, including 300 apartments for sale, expected revenue of about NIS 1.06 billion, and expected gross profit of about NIS 210.3 million. Estimated completion is Q4 2031, and at the end of March the project was still not close enough to be treated as near-term cash: the company is updating the design plan following Amendment 163 to the Planning and Building Law, the complex had not yet received final qualifying urban-renewal declaration, and dissenting tenants remained.
Those facts explain why bringing in a partner can make sense even when it reduces the upside. In a project like this, the risk is not only whether the apartments eventually get built. It is who funds the years until then. After a quarter in which operating cash flow was negative NIS 56.6 million and cash fell to NIS 15.4 million, full La Guardia exposure is both a promise and a burden. Selling 49% transfers part of that burden to a partner while reducing Anshei Hair's direct share of the expected project gross profit.
On a 100% project-estimate basis, 49% of the expected gross profit is about NIS 103 million. That is not the transaction value, not certain profit, and not free cash flow for shareholders. It is the scale of direct upside the company is choosing to share in exchange for cash, a partner, and shared funding. The transaction is therefore not one-directionally good or bad. It mainly makes an oversized project more manageable, at the cost of less full exposure to the final outcome.
| Transaction Component | Economic Meaning |
|---|---|
| Sale of 49% of La Guardia | Lower funding need and concentration in the largest backlog project, but also a lower direct share of future profit |
| NIS 32 million in cash | NIS 16 million near signing, with the balance paid in two installments, the last on January 1, 2027 |
| About NIS 3.5 million reimbursement | Participation in 49% of investment already made, half on December 31, 2026 and the balance near receipt of a building permit |
| Joint venture agreement | Each party is expected to fund its share and share project profits according to ownership |
The First Payment Buys Time, Not the Whole Project
The relevant cash frame here is flexibility after actual cash uses, not normalized profitability from a future project. The question is how much money comes into the company after operating needs, investments, debt, and other real cash uses during the interim period before La Guardia can fund itself. The first NIS 16 million payment, which is due near signing, is meaningful against a NIS 15.4 million cash balance at the end of March, but it is small relative to a project whose expected revenue exceeds NIS 1 billion and whose estimated completion is only in 2031.
The payment schedule also creates a timing gap. Half of the cash consideration is expected near signing, but the remaining NIS 16 million is spread through January 1, 2027. The about NIS 3.5 million reimbursement is also staged: half at the end of 2026 and the balance near the building permit. The deal helps 2026, but it does not remove the need to see planning progress, closing of conditions, and actual cash receipt.
That is where the deal is sharper than its headline. Looking only at the stated price, it can read as a sale of part of a large project. Looking at the payment schedule and project status, it looks more like interim financing with a strategic partner. Anshei Hair gets liquidity and reduces the obligation to fund the long path to permit alone, but shareholders get smaller direct exposure to La Guardia itself.
Ibn Gabirol Adds Diversification, But It Does Not Yet Replace La Guardia
The other side of the transaction matters because it prevents the deal from being a simple asset sale. Menrav is expected to transfer to Anshei Hair 49% of the rights and obligations in two Ibn Gabirol projects, with no consideration paid by Anshei Hair. But these are still not equivalent to La Guardia in maturity or disclosure.
Ibn Gabirol 117-119 is relatively advanced: 81% of rights holders have signed, above the required 66% threshold, dissenting tenants remain, a building-permit application has been filed, and the zoning plan has been approved. The current plan includes 55 new apartments, of which 27 are for sale, plus 1,878 square meters of commercial and employment space. That is economically meaningful exposure, but it still has to pass objection, permit, and execution stages.
Ibn Gabirol 113-115 is weaker as a current economic anchor. The transfer relates to an option to carry out a project, including a TAMA agreement that will be signed with tenants if it is signed. In addition, the validity of the Ibn Gabirol agreements depends on tenant-representative approval, and in 113-115 also on a special majority of tenants signing. Some deadlines can be extended, but the final date is December 31, 2026.
Ibn Gabirol therefore improves diversification, but it does not erase the La Guardia trade-off. It gives Anshei Hair another possible future profit path, with a partner and without acquisition consideration, but that path is still more conditional, smaller, and less certain. It becomes a true replacement asset only if approvals are completed and the projects move toward permits, financing, and sales.
The Next Read Depends on Cash Received and Approvals Closed
The conclusion is that the Menrav deal is primarily a pressure-reduction transaction. It cuts Anshei Hair's exposure to one very large project, brings in staged cash, and attaches a partner that should fund its share. It does not prove that La Guardia has already become accessible value, and it does not leave the company with the same direct upside it had before the deal.
The points that will determine the read from here are simpler than the legal structure: whether the payments arrive on schedule, whether La Guardia moves toward final declaration and permit, and whether the Ibn Gabirol conditions close by December 31, 2026. Until then, the deal deserves credit as a risk and funding reducer. It does not yet deserve credit as an event that crystallizes the full value of the largest project in the backlog.
Disclosure: Deep TASE analyses are general informational, research, and commentary content only. They do not constitute investment advice, investment marketing, a recommendation, or an offer to buy, sell, or hold any security, and are not tailored to any reader's personal circumstances.
The author, site owner, or related parties may hold, buy, sell, or otherwise trade securities or financial instruments related to the companies discussed, before or after publication, without prior notice and without any obligation to update the analysis. Publication of an analysis should not be read as a statement that any position does or does not exist.
The analysis may contain errors, omissions, or information that changes after publication. Readers should review official filings and primary sources before making decisions.